Cargando…

T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens

INTRODUCTION: The profile of immune activation markers in tuberculosis and HIV-infected patients is already known. The impact of simultaneous infections on the immune parameters is still not fully explored. METHODS: We conducted a prospective study to estimate trajectories of activated T cell subset...

Descripción completa

Detalles Bibliográficos
Autores principales:	da Silva, Tatiana P., Giacoia-Gripp, Carmem B. W., Schmaltz, Carolina A., Sant` Anna, Flavia M., Rolla, Valeria, Morgado, Mariza G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686825/ https://www.ncbi.nlm.nih.gov/pubmed/23840403 http://dx.doi.org/10.1371/journal.pone.0066095

Ejemplares similares

Risk factors for increased immune reconstitution in response to Mycobacterium tuberculosis antigens in tuberculosis HIV-infected, antiretroviral-naïve patients
por: da Silva, Tatiana Pereira, et al.
Publicado: (2017)

Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial
por: Xavier, Mariana S., et al.
Publicado: (2018)

Changes in the NK Cell Repertoire Related to Initiation of TB Treatment and Onset of Immune Reconstitution Inflammatory Syndrome in TB/HIV Co-infected Patients in Rio de Janeiro, Brazil—ANRS 12274
por: Giacoia-Gripp, Carmem Beatriz Wagner, et al.
Publicado: (2019)

Clinical and genetic markers associated with tuberculosis, HIV-1 infection, and TB/HIV-immune reconstitution inflammatory syndrome outcomes
por: de Sá, Nathalia Beatriz Ramos, et al.
Publicado: (2020)

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?
por: Schmaltz, Carolina Arana Stanis, et al.
Publicado: (2019)

Factors Impacting Early Mortality in Tuberculosis/HIV Patients: Differences between Subjects Naïve to and Previously Started on HAART
por: Schmaltz, Carolina Arana Stanis, et al.
Publicado: (2012)

Inflammasome genetic variants are associated with tuberculosis, HIV-1 infection, and TB/HIV-immune reconstitution inflammatory syndrome outcomes
por: de Sá, Nathalia Beatriz Ramos, et al.
Publicado: (2022)

Impact of adverse drug reactions on the outcomes of tuberculosis treatment
por: Sant´Anna, Flávia M., et al.
Publicado: (2023)

Antituberculous Serum
Publicado: (1899)

Tuberculosis Treatment Outcomes and Factors Associated with Each of Them in a Cohort Followed Up between 2010 and 2014
por: Cardoso, Mayara A., et al.
Publicado: (2017)

Tuberculosis associated thrombocytopenic purpura: effectiveness of antituberculous therapy
por: Borie, Raphael, et al.
Publicado: (2009)

Management of Severe Gastrointestinal Tuberculosis with Injectable Antituberculous Drugs
por: Goldani, Luciano Z., et al.
Publicado: (2015)

Impact of Persistent Anemia on Systemic Inflammation and Tuberculosis Outcomes in Persons Living With HIV
por: Demitto, Fernanda O., et al.
Publicado: (2020)

High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected individuals despite low HIV viral load
por: Santos-Oliveira, Joanna R, et al.
Publicado: (2010)

Evaluation of Cellular Phenotypes Implicated in Immunopathogenesis and Monitoring Immune Reconstitution Inflammatory Syndrome in HIV/Leprosy Cases
por: Giacoia-Gripp, Carmem Beatriz Wagner, et al.
Publicado: (2011)

On Treatment with Antituberculous Serum
Publicado: (1904)

Cutaneous tuberculosis and HIV infection at a referral centre in Rio de Janeiro, Brazil
por: Mann, Danielle, et al.
Publicado: (2018)

Anemia in tuberculosis cases: A biomarker of severity?
por: de Mendonça, Edson Beyker, et al.
Publicado: (2021)

Correction: Anemia in tuberculosis cases: A biomarker of severity?
por: de Mendonça, Edson Beyker, et al.
Publicado: (2021)

Influence of the Efavirenz Micronization on Tableting and Dissolution
por: Pinto, Eduardo Costa, et al.
Publicado: (2012)

Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

Impact of immunopathology on the antituberculous activity of pyrazinamide
por: Blanc, Landry, et al.
Publicado: (2018)

Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil
por: Demitto, Fernanda O., et al.
Publicado: (2019)

Severe gastrintestinal bleeding as an unusual presentation of pediatric tuberculosis: a situation for injectable antituberculous drugs use?
por: Santos, Ana Carolina Etrusco Zaroni, et al.
Publicado: (2020)

Drug Resistance Characteristics of Mycobacterium tuberculosis Isolates From Patients With Tuberculosis to 12 Antituberculous Drugs in China
por: Wu, Xiaocui, et al.
Publicado: (2019)

Pneumatocele formation in adult pulmonary tuberculosis during antituberculous chemotherapy: a case report
por: Wan-Hsiu, Liao, et al.
Publicado: (2009)

Paradoxical Tuberculomas after Completion of Antituberculous Treatment
por: Shah, Ira, et al.
Publicado: (2012)

AdDRESSing T-cell responses to antituberculous drugs
por: Pavlos, R., et al.
Publicado: (2017)

Renal BCGosis managed conservatively with antituberculous medications
por: Elmekresh, Amr, et al.
Publicado: (2023)

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals
por: Cain, Lauren E., et al.
Publicado: (2016)

A Case of Obstructive Jaundice Caused by Paradoxical Reaction during Antituberculous Chemotherapy for Abdominal Tuberculosis
por: Lee, Yun Jung, et al.
Publicado: (2009)

Targeting Mycobacterium tuberculosis Tumor Necrosis Factor Alpha-Downregulating Genes for the Development of Antituberculous Vaccines
por: Olsen, Aaron, et al.
Publicado: (2016)

The Effect of Combining Natural Terpenes and Antituberculous Agents against Reference and Clinical Mycobacterium tuberculosis Strains
por: Sieniawska, Elwira, et al.
Publicado: (2018)

ANTITUBERCULOUS IMMUNITY IN MICE VACCINATED WITH KILLED TUBERCLE BACILLI
por: Dubos, René J., et al.
Publicado: (1953)

Early monitoring for detection of antituberculous drug-induced hepatotoxicity
por: Lee, Chang Min, et al.
Publicado: (2016)

Lansoprazole is an antituberculous prodrug targeting cytochrome bc(1)
por: Rybniker, Jan, et al.
Publicado: (2015)

Efavirenz Conceptions and Regimen Management in a Prospective Cohort of Women on Antiretroviral Therapy
por: Schwartz, Sheree, et al.
Publicado: (2012)

Effectiveness of Efavirenz-Based Regimens in Young HIV-Infected Children Treated for Tuberculosis: A Treatment Option for Resource-Limited Settings
por: van Dijk, Janneke H., et al.
Publicado: (2013)

Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapy
por: Sheikh, Javaid A, et al.
Publicado: (2011)

A Newly Developed Pericardial Tuberculoma During Antituberculous Therapy
por: Kim, Sang Min, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jlcqpilhc3i1dunq020kpuvja5